Duopharma Biotech Bhd Stock Revenue
| 7148 Stock | 1.28 0.01 0.78% |
Duopharma Biotech Bhd fundamentals help investors to digest information that contributes to Duopharma Biotech's financial success or failures. It also enables traders to predict the movement of Duopharma Stock. The fundamental analysis module provides a way to measure Duopharma Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Duopharma Biotech stock.
Duopharma |
Duopharma Biotech Bhd Company Revenue Analysis
Duopharma Biotech's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Duopharma Biotech Revenue | 639.17 M |
Most of Duopharma Biotech's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Duopharma Biotech Bhd is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, Duopharma Biotech Bhd reported 639.17 M of revenue. This is 91.62% lower than that of the Healthcare sector and significantly higher than that of the Pharmaceuticals industry. The revenue for all Malaysia stocks is 93.23% higher than that of the company.
Duopharma Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Duopharma Biotech's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Duopharma Biotech could also be used in its relative valuation, which is a method of valuing Duopharma Biotech by comparing valuation metrics of similar companies.Duopharma Biotech is currently under evaluation in revenue category among its peers.
Duopharma Fundamentals
| Return On Equity | 10.93 | |||
| Current Valuation | 1.78 B | |||
| Price To Book | 2.32 X | |||
| Price To Sales | 2.12 X | |||
| Revenue | 639.17 M | |||
| EBITDA | 121.38 M | |||
| Net Income | 82.98 M | |||
| Cash And Equivalents | 31.5 M | |||
| Total Debt | 297.8 M | |||
| Cash Flow From Operations | 43.2 M | |||
| Market Capitalization | 1.56 B | |||
| Total Asset | 1.16 B | |||
| Z Score | 3.0 | |||
| Annual Yield | 0.04 % | |||
| Net Asset | 1.16 B | |||
| Last Dividend Paid | 0.095 |
About Duopharma Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Duopharma Biotech Bhd's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Duopharma Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Duopharma Biotech Bhd based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Duopharma Stock
Duopharma Biotech financial ratios help investors to determine whether Duopharma Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Duopharma with respect to the benefits of owning Duopharma Biotech security.